Cardiff Oncology
Cardiff Oncology is develops drugs that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers.
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed Cardiff Oncology Information
Geographic Data
Address:
City: San Diego
State: California
Zip:
Country: United States
Financial Info
Stage:
post ipo equity
Raised Last:
$15M
Raised Total:$80M
Social
Metrics
3,659,849Website Global Rank
3,572Website Monthly Traffic
Twitter Followers
Description
Cardiff Oncology is a clinical-stage oncology therapeutics company developing drugs that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers. It has a broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. The company offers its PCM technology at its CLIA/CAP-accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. Cardiff Oncology (formerly known as Trovagene) was founded in 1999 and is headquartered in San Diego, California.
Contact Phone:
Contact Email:
Cardiff Oncology went public on 7/27/2004 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
7/27/2004
Ticker Symbol:
CRDF
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 11/2021 | Post-IPO Equity | 1 | $15M |
Pfizer Breakthrough Growth Initiative Pfizer Breakthrough Growth Initiative Pfizer Breakthrough Growth Initiative Pfizer Breakthrough Growth Initiative |
3/2012 | Post-IPO Equity | $6.6M | 7/2014 | Post-IPO Debt | 2 | $15M |
Oxford Finance LLC Silicon Valley Bank Oxford Finance LLC Silicon Valley Bank |
6/2020 | Post-IPO Equity | 2 | $13.5M |
Acorn Bioventures CAM Capital Acorn Bioventures CAM Capital Acorn Bioventures CAM Capital Acorn Bioventures CAM Capital |
12/2012 | Post-IPO Equity | $3.8M | 7/2017 | Post-IPO Equity | $7.1M | 6/2018 | Post-IPO Equity | $18M | 4/2019 | Post-IPO Equity | $1.5M |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
